Xanomeline and Trospium Chloride Versus Placebo for the Treatment of Schizophrenia: A Post Hoc Analysis of Number Needed to Treat, Number Needed to Harm, and Likelihood to Be Helped or Harmed
Leslie Citrome,1 Nichole M Neugebauer,2 Alicia A Meli,2 Judith Kando2 1Department of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, NY, USA; 2Medical Affairs, Bristol Myers Squibb, Princeton, NJ, USACorrespondence: Leslie Citrome, Department of Psychiatry and Behavioral Scie...
Saved in:
| Main Authors: | Citrome L, Neugebauer NM, Meli AA, Kando J |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2025-04-01
|
| Series: | Neuropsychiatric Disease and Treatment |
| Subjects: | |
| Online Access: | https://www.dovepress.com/xanomeline-and-trospium-chloride-versus-placebo-for-the-treatment-of-s-peer-reviewed-fulltext-article-NDT |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Does KarXT (xanomeline-trospium) represent a novel approach to schizophrenia management? A GRADE-assessed systematic review and meta-analysis of randomized controlled clinical trials
by: Hazem E. Mohammed, et al.
Published: (2025-03-01) -
Evaluating the Role and Efficacy of Cobenfy (Xanomeline and Trospium Chloride) in Schizophrenia Treatment - review
by: Michał Mazur, et al.
Published: (2025-04-01) -
Early outpatient clinical experience with xanomeline and trospium chloride for schizophrenia: a case report
by: Maxwell Zachary Price, et al.
Published: (2025-06-01) -
Adjuvant systemic therapy in melanoma: Relative versus absolute benefit; the number needed to treat (NNT) versus the number needed to harm (NNH)?
by: Alexander C.J. van Akkooi, et al.
Published: (2024-12-01) -
Is muscarinic receptor agonist effective and tolerant for schizophrenia?
by: Xiaonan Guo, et al.
Published: (2025-04-01)